With the appearance of the resistance against targeted EGFR therapy, current researches about EGFR principally focus on TKIs resistance and seeking the best way to overcome the resistance mechanisms, incorporating the EGFR T790M mutations (approximately 50% in resistant cancers), PIK3CA mutations, and MET amplification. The gene discussed is PIK3CA; the disease is cancer.